immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapie… Read more
immatics biotechnologies GmbH (IMTXW) - Net Assets
Latest net assets as of March 2025: $536.61 Million USD
Based on the latest financial reports, immatics biotechnologies GmbH (IMTXW) has net assets worth $536.61 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($641.69 Million) and total liabilities ($105.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $536.61 Million |
| % of Total Assets | 83.62% |
| Annual Growth Rate | N/A |
| 5-Year Change | 451.38% |
| 10-Year Change | N/A |
| Growth Volatility | 338.55 |
immatics biotechnologies GmbH - Net Assets Trend (2018–2024)
This chart illustrates how immatics biotechnologies GmbH's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for immatics biotechnologies GmbH (2018–2024)
The table below shows the annual net assets of immatics biotechnologies GmbH from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $574.84 Million | +155.39% |
| 2023-12-31 | $225.08 Million | +5.59% |
| 2022-12-31 | $213.16 Million | +785.86% |
| 2021-12-31 | $24.06 Million | -76.92% |
| 2020-12-31 | $104.26 Million | +355.31% |
| 2019-12-31 | $-40.84 Million | -345.26% |
| 2018-12-31 | $-9.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to immatics biotechnologies GmbH's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38791796300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.22 Million | 0.21% |
| Other Comprehensive Income | $1.03 Million | 0.18% |
| Other Components | $1.16 Billion | 202.17% |
| Total Equity | $574.84 Million | 100.00% |
immatics biotechnologies GmbH Competitors by Market Cap
The table below lists competitors of immatics biotechnologies GmbH ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LCS Imobiliar SA
RO:LCSI
|
$35.28K |
|
KLASSIK RADIO N - Dusseldorf Stock Exchang
DU:KA8
|
$35.31K |
|
HYPE3F
SA:HYPE3F
|
$35.33K |
|
Ceylon Tea Services PLC
CM:CTEAN0000
|
$35.34K |
|
THES. WATER S.+S. EO 112
F:T9W
|
$35.25K |
|
Sentry Select Primary Metals Corp
TO:PME
|
$35.23K |
|
7631
TW:7631
|
$35.22K |
|
Derkwoo Electronics Co. Ltd.
KO:263600
|
$35.11K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in immatics biotechnologies GmbH's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 225,084,000 to 574,842,000, a change of 349,758,000 (155.4%).
- Net income of 15,218,000 contributed positively to equity growth.
- New share issuances of 343,010,000 increased equity.
- Other comprehensive income increased equity by 2,667,000.
- Other factors decreased equity by 11,137,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $15.22 Million | +2.65% |
| Share Issuances | $343.01 Million | +59.67% |
| Other Comprehensive Income | $2.67 Million | +0.46% |
| Other Changes | $-11.14 Million | -1.94% |
| Total Change | $- | 155.39% |
Book Value vs Market Value Analysis
This analysis compares immatics biotechnologies GmbH's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.17 | $0.00 | x |
| 2019-12-31 | $-0.67 | $0.00 | x |
| 2020-12-31 | $2.17 | $0.00 | x |
| 2021-12-31 | $0.38 | $0.00 | x |
| 2022-12-31 | $3.10 | $0.00 | x |
| 2023-12-31 | $2.79 | $0.00 | x |
| 2024-12-31 | $5.38 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently immatics biotechnologies GmbH utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.77%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.21x
- Recent ROE (2.65%) is above the historical average (-91.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -834.06% | 0.06x | 0.00x | $-30.40 Million |
| 2019 | 0.00% | -172.05% | 0.14x | 0.00x | $-27.56 Million |
| 2020 | -219.99% | -733.84% | 0.12x | 2.44x | $-239.77 Million |
| 2021 | -395.05% | -273.45% | 0.20x | 7.26x | $-97.47 Million |
| 2022 | 17.60% | 21.71% | 0.42x | 1.91x | $16.20 Million |
| 2023 | -43.09% | -179.63% | 0.11x | 2.27x | $-119.50 Million |
| 2024 | 2.65% | 9.77% | 0.22x | 1.21x | $-42.27 Million |
Industry Comparison
This section compares immatics biotechnologies GmbH's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| immatics biotechnologies GmbH (IMTXW) | $536.61 Million | 0.00% | 0.20x | $35.27K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |